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models for patients with pediatric acute respiratory distress syn-
drome.
Design: Leveraging additional data collection from a preplanned 
ancillary study (Version 1) of the multinational Pediatric Acute 
Respiratory Distress syndrome Incidence and Epidemiology 
study, we identified predictors of mortality. Separate models were 
built for the entire Version 1 cohort, for the cohort excluding neu-
rologic deaths, for intubated subjects, and for intubated subjects 
excluding neurologic deaths. Models were externally validated in a 
cohort of intubated pediatric acute respiratory distress syndrome 
patients from the Children’s Hospital of Philadelphia.
Setting: The derivation cohort represented 100 centers world-
wide; the validation cohort was from Children’s Hospital of Phil-
adelphia.
Patients: There were 624 and 640 subjects in the derivation and 
validation cohorts, respectively.
Interventions: None.
Measurements and Main Results: The model for the full cohort 
included immunocompromised status, Pediatric Logistic Organ 
Dysfunction 2 score, day 0 vasopressor-inotrope score and fluid 
balance, and Pao2/Fio2 6 hours after pediatric acute respiratory 
distress syndrome onset. This model had good discrimination (area 
under the receiver operating characteristic curve 0.82), calibration, 
and internal validation. Models excluding neurologic deaths, for 
intubated subjects, and for intubated subjects excluding neuro-
logic deaths also demonstrated good discrimination (all area under 
the receiver operating characteristic curve ≥ 0.84) and calibration. 
In the validation cohort, models for intubated pediatric acute res-
piratory distress syndrome (including and excluding neurologic 
deaths) had excellent discrimination (both area under the receiver 
operating characteristic curve ≥ 0.85), but poor calibration. After 
revision, the model for all intubated subjects remained miscali-
brated, whereas the model excluding neurologic deaths showed 
perfect calibration. Mortality models also stratified ventilator-free 
days at 28 days in both derivation and validation cohorts.
Conclusions: We describe predictive models for mortality in pe-
diatric acute respiratory distress syndrome using readily avail-
able variables from day 0 of pediatric acute respiratory distress 
syndrome which outperform severity of illness scores and which 
demonstrate utility for composite outcomes such as ventilator-free 
days. Models can assist with risk stratification for clinical trials. 
(Crit Care Med 2020; 48:e514–e522)
Key Words: mortality; pediatric acute respiratory distress 
syndrome; prediction; risk stratification; ventilator-free days
Acute respiratory distress syndrome (ARDS) is charac-terized by acute hypoxemic respiratory failure from noncardiogenic pulmonary edema. Despite inclusion 
of pediatric subjects in the initial description of ARDS (1), nei-
ther the 1994 American-European Consensus Conference (2) 
nor the 2012 Berlin revised definitions of ARDS (3) addressed 
pediatric considerations. To inform study design in children 
with ARDS, the Pediatric Acute Lung Injury Consensus Con-
ference (PALICC) developed a specific definition for pedi-
atric ARDS (PARDS) in 2015 (4). Notable differences in the 
PALICC definition include use of oxygenation index (OI), 
rather than Pao
2
/Fio
2
, for severity stratification; explicit use 
of alternative stratification using peripheral oxygen saturation 
(Spo
2
)(oxygen saturation index [OSI]); and inclusion of uni-
lateral, in addition to bilateral, infiltrates on chest radiograph. 
Both the Berlin and PALICC definitions highlighted the need 
to better stratify risk, with PALICC specifically recommending 
the development of prognostic scores to stratify mortality (4, 
5). Appropriate risk stratification would permit prognostic en-
richment (restriction of trial eligibility to those at highest risk 
of poor outcome) for clinical trials (6), as well as allow testing 
for heterogeneity of treatment effect (7).
Recently, the Pediatric ARDS Incidence and Epidemiology 
(PARDIE) study was completed to assess the utility of the 
PALICC definition, identifying 708 subjects from 145 PICUs 
worldwide (8). PARDIE identified three-fold more cases of 
PARDS using PALICC criteria, compared with Berlin, with 
improved mortality discrimination with PALICC severity 
categories. In a preplanned ancillary study (dubbed Version 
1 [V1]), additional data were collected to assess predictors of 
mortality. Herein, we present the development and validation 
of mortality prediction models in PARDS. We hypothesized 
that a combination of clinical variables could reliably estimate 
the probability of PICU mortality.
MATERIALS AND METHODS
The full Methods are available in the Data Supplement (Sup-
plemental Digital Content 1, http://links.lww.com/CCM/F458). 
The study was designed and reported consistent with the rec-
ommendations of the Transparent Reporting of a multivariable 
prediction model for Individual Prognosis or Diagnosis state-
ment (Appendix 1, Supplemental Digital Content 1, http://links.
lww.com/CCM/F458). The Children’s Hospital of Los Angeles 
(CHLA, Los Angeles, CA) was the clinical and data coordinating 
center. The protocol was first approved by the CHLA Institu-
tional Review Board (IRB). PARDIE sites obtained ethical ap-
proval from their local IRB or relied on the central CHLA IRB.
Derivation (PARDIE V1) Cohort
PARDIE consisted of 708 subjects from 145 PICUs in 27 pre-
dominantly high-income countries (8), prospectively screened 
over 5 days during 10 nonconsecutive weeks between May 
2016 and June 2017, with each site deciding a priori whether to 
participate in the ancillary studies. V1 included additional data 
from 100 centers (Appendix 2, Supplemental Digital Content 
1, http://links.lww.com/CCM/F458). Patients were eligible for 
PARDIE if they newly met PALICC PARDS criteria. We col-
lected data for the first 3 days after PARDS diagnosis, including 
demographics, center characteristics, geoeconomic categoriza-
tion, oxygenation, ventilatory support, radiographs, severity 
of illness measured using the Pediatric Index of Mortality 
(PIM) 3 and Pediatric Risk of Mortality (PRISM) IV scores, 
and comorbidities. Additional data collected for V1 included 
daily (calendar day) organ failure (Pediatric Logistic Organ 
Dysfunction [PELOD] 2 score), vasopressor requirement, fluid 
balance, and use of ancillary therapies.
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External Validation Cohort
We externally validated the predictive models using a prospec-
tive cohort of intubated children meeting Berlin ARDS crite-
ria from the PICU of the Children’s Hospital of Philadelphia 
(CHOP), a 60-bed PICU in a quaternary North American chil-
dren’s hospital, between July 2011 and June 2018. As CHOP was 
a participant in PARDIE, overlapping subjects were excluded.
Definitions and Outcomes
The primary outcome was PICU mortality. Secondary out-
comes include duration of ventilation in survivors and venti-
lator-free days (VFDs) at 28 days. Oxygenation was measured 
using Pao
2
/Fio
2
 and Spo
2
/Fio
2
 in all subjects, and OI and 
OSI in intubated subjects (9, 10). For all analyses, noninva-
sive measures were converted to invasive equivalents using 
published equations (9). Vasopressor-inotrope score was do-
pamine (µg/kg/min) × 1 + dobutamine (µg/kg/min) × 1 + ep-
inephrine (µg/kg/min) × 100 + norepinephrine (µg/kg/min) × 
100 + milrinone (µg/kg/min) × 10 (11). The designation “im-
munocompromised” required presence of an oncologic diag-
nosis, immunodeficiency, stem cell or organ transplant, or a 
rheumatologic or inflammatory condition receiving immuno-
suppression (12, 13). Countries were grouped by geographical 
region and economic status using 2016 World Bank classifica-
tions (14). A single cause of death was assigned by site investi-
gators: hypoxemia, refractory shock, multisystem organ failure 
(MSOF), brain death, other neurologic cause, or other.
Development of a Model for Mortality Prediction
Our primary aim was to construct a parsimonious model of 
clinical variables on day of PARDS onset (day 0) associated 
with PICU mortality for use in risk prediction. We did this in 
two steps: penalized regression followed by variable reduction 
using the Bayesian information criterion (BIC), detailed in 
the Data Supplement (Supplemental Digital Content 1, http://
links.lww.com/CCM/F458). Internal validation was evaluated 
by 10-fold cross-validation and assessment of model perfor-
mance in prespecified subgroups. Calibration and fit were 
assessed using the calibration belt (15). Discrimination for 
PICU mortality was assessed by calculating area under the re-
ceiver operating characteristic (AUROC) curve.
The primary model was developed using the entire V1 co-
hort, which included intubated and noninvasively ventilated 
subjects with PARDS, and all-cause mortality. Three subgroup 
models were built. First, as subjects dying of a neurologic eti-
ology may have different predictors of mortality than those 
dying of shock, MSOF, or hypoxemia (16), we repeated the 
analysis excluding those who died primarily due to a neuro-
logic cause. Second, we repeated the analysis in patients inva-
sively ventilated within 6 hours of PARDS diagnosis. Third, we 
repeated the analysis in invasively ventilated subjects excluding 
those who died from a neurologic cause.
External Validation of the Model
Models were validated using a cohort of children with Berlin 
ARDS from CHOP. As all CHOP subjects were intubated, we 
only assessed models for invasively ventilated subjects. Cali-
bration, fit, and discrimination were reported. Since the model 
was derived from a multicenter cohort, we reasoned that if cal-
ibration was poor, the model would be revised in this cohort by 
reestimation of the coefficients and intercept (17).
Utility of the Mortality Model to Stratify Ventilator-
Free Days
We assessed whether models developed for mortality were 
calibrated for VFDs in both derivation and validation cohorts. 
Subjects were split into quartiles of predicted mortality for 
each of the models. For each quartile, VFDs were modeled as 
a competing risk, treating discontinuation of ventilation as the 
primary outcome, and death as a competing event. Outcomes 
were censored after 28 days, making this equivalent to VFDs 
at 28 days (18). Models were constructed for all patients (in-
vasive and noninvasive VFDs) and for intubated patients (in-
vasive VFDs) in the derivation cohort and limited to invasive 
VFDs for the validation cohort. Noninvasive ventilation was 
defined as oro-nasal mask continuous positive airway pressure 
or bilevel positive airway pressure. High-flow oxygen was not 
counted as noninvasive support.
Development of a Model for Identifying Predictors of 
Ventilator Duration
As mortality in PARDS is low, length of ventilation in survivors 
is an important contributor to VFDs. Therefore, we separately 
constructed models to identify predictors of total (invasive and 
noninvasive) and invasive ventilator duration in survivors. We 
modeled ventilator duration as time to event analyses using 
Cox regression with clustering by site, censored at 28 days, 
with variable selection based on BIC optimization, similar to 
the mortality models.
RESULTS
Description of the V1 Cohort
Description of the V1 cohort (n = 624, 108 deaths) stratified 
by PICU survival status is presented in Table 1, and more 
completely in Supplementary Table 1 (Supplemental Dig-
ital Content 1, http://links.lww.com/CCM/F458). Nonsurvi-
vors had greater severity of illness scores, more comorbidities, 
and higher vasopressor scores and fluid balance on the day 
of PARDS diagnosis (day 0). Nonsurvivors were more likely 
to have worse oxygenation, irrespective of whether invasively 
ventilated or not. Finally, nonsurvivors were more likely to 
come from World Bank-designated middle-income countries. 
Of the 108 nonsurvivors, 28 (26%) had a primary neurologic 
etiology as a cause of death.
Predictive Models for PICU Mortality from the V1 
Cohort
Table 2 shows the final model for PICU mortality in the entire 
cohort. PELOD 2 on day of PARDS diagnosis (day 0), vaso-
pressor score and fluid balance (mL/kg) on day 0 of PARDS, im-
munocompromised status, and Pao
2
/Fio
2
 6 hours after PARDS 
Online Clinical Investigations
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TABLE 1. Description of the Pediatric Acute Respiratory Distress syndrome Incidence and 
Epidemiology Version 1 Cohort Stratified by Mortality
Variable
Whole Cohort  
(n = 624)
Survivors  
(n = 516)
Nonsurvivors  
(n = 108) p
Demographics
 Age (yr) (n = 619), mean ± sd 6.1 ± 6.4 6.0 ± 6.3 6.5 ± 6.6 0.513
 Female/male (%) (n = 623) 247/376  
(40/60)
205/310  
(40/60)
42/66  
(39/61)
0.914 
 Nonwhite race (%) (n = 619) 243 (39) 193 (38) 50 (46) 0.105
 Hispanic ethnicity (%) (n = 621) 139 (22) 104 (20) 35 (32) 0.008
Admission source (%) (n = 623)
 Emergency department 286 (46) 245 (48) 41 (38) 0.018
 Inpatient floor 219 (35) 168 (33) 51 (48)  
 Other 118 (19) 102 (20) 16 (15)  
Severity of illness, mean ± sd
 Pediatric Index of Mortality 3 (admission) –3.6 ± 2.1 –3.9 ± 1.7 –2.1 ± 2.7 < 0.001
 Pediatric Risk of Mortality IV (admission) (n = 622) 9.0 ± 8.3 7.7 ± 7.1 15.0 ± 10.5 < 0.001
 Pediatric Logistic Organ Dysfunction 2 (PARDS onset) (n = 621) 5.4 ± 3.3 4.9 ± 2.8 7.9 ± 4.3 < 0.001
Vasopressor-inotrope score day 0 (n = 619), mean ± sd 11.6 ± 29.6 7.4 ± 21.4 32.1 ± 48.9 < 0.001
Fluid balance day 0 (mL/kg) (n = 609), mean ± sd 26.6 ± 43.4 23.7 ± 39.3 41.2 ± 57.1 < 0.001
Preexisting comorbidities (%)
 None 233 (37) 208 (40) 25 (23) 0.001
 Immunocompromised 82 (13) 42 (8) 40 (37) < 0.001
PARDS etiology (%)
 Pneumonia 392 (63) 341 (66) 51 (47) < 0.001
 Nonpulmonary sepsis 121 (19) 86 (17) 35 (32)  
 Other 111 (18) 89 (17) 22 (20)  
Pao2/Fio2, mean ± sd
 PARDS diagnosisa 142 ± 83 148 ± 84 115 ± 69 < 0.001
 6 hr 177 ± 108 185 ± 109 138 ± 91 < 0.001
Oxygenation index in intubated subjects, mean ± sd
 PARDS diagnosis (n = 485)a 14.1 ± 11.1 12.8 ± 9.8 20.5 ± 13.9 < 0.001
 6 hr (n = 531)a 12.5 ± 11.2 10.7 ± 8.8 20.5 ± 16.5 < 0.001
Pediatric Acute Lung Injury Consensus Conference categories (%)
 Noninvasive 139 (22) 117 (23) 22 (20) < 0.001
 Mild 200 (32) 175 (34) 25 (23)  
 Moderate 133 (21) 121 (23) 12 (11)  
 Severe 152 (24) 103 (20) 49 (45)  
Geoeconomic status (%)
 High income: North America 413 (66) 351 (68) 62 (57) 0.001
 High income: Europe 91 (15) 77 (15) 14 (13)  
 High income: rest of world 36 (6) 32 (6) 4 (4)  
 Middle income 84 (13) 56 (11) 28 (26)  
PARDS = pediatric acute respiratory distress syndrome.
a Invasive measures of oxygenation (Pao2/Fio2 and oxygenation index) include values derived from noninvasive (peripheral oxygen saturation [Spo2]-based) 
analogies (Spo2/Fio2 and oxygenation saturation index), which have been converted to Pao2/Fio2 and oxygenation index using published equations.
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diagnosis were included. Neither noninvasive ventilation nor 
presence of unilateral infiltrates were retained as predictors. 
The model demonstrated good discrimination (AUROC, 0.82; 
95% CI, 0.78–0.87), calibration, and fit (Table 3 and Fig. 1A). 
Ten-fold cross-validation (Table 3) and testing in prespecified 
subgroups (Supplementary Table 2, Supplemental Digital 
Content 1, http://links.lww.com/CCM/F458) suggested good 
internal validity (all AUROC ≥ 0.80).
Separate models (Supplementary Table 3, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F458) were 
constructed for the cohort excluding those who died of neu-
rologic causes, for those invasively ventilated 6 hours after 
PARDS diagnosis, and for those invasively ventilated excluding 
neurologic deaths. Most of the same variables were retained 
as predictors in all three subgroup models, with the addition 
of coming from a middle-income country for the cohort ex-
cluding neurologic deaths, the substitution of OI (for Pao
2
/
Fio
2
) in the invasively ventilated models, and the removal 
of day 0 fluid balance in the invasively ventilated models. 
Retention of OI, rather than Pao
2
/Fio
2
, resulted in lower BIC 
in models for intubated subjects. All models (Table 3) demon-
strated good discrimination (AUROC ≥ 0.84) with retention of 
this property after cross-validation (cross-validated AUROC ≥ 
0.83). All models demonstrated good fit (Fig. 1). The models 
for the intubated cohort had higher AUROC than the severity 
of illness scores PIM 3, PRISM IV, and PELOD 2, as well as a 
published (19) simplified prediction model (all p < 0.05 when 
comparing AUROC; Table 4).
Performance of Models in the CHOP Validation 
Cohort
Comparison of the PARDIE V1 and the CHOP cohorts are pro-
vided in Supplementary Table 4 (Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/F458). By design, the CHOP 
cohort excluded subjects requiring chronic ventilation at base-
line and with unrepaired congenital heart disease, and required 
subjects to be intubated with bilateral infiltrates. Mortality was 
similar for both the V1 (17%) and CHOP (18%) cohorts.
Both predictive models (intubated subjects, including and 
excluding neurologic deaths) had good discrimination (both 
AUROC ≥ 0.85; Table 4) but poor calibration (Supplementary 
Fig. 1, A and B, Supplemental Digital Content 1, http://links.
lww.com/CCM/F458), with overestimation of mortality when 
applied without modification to the CHOP cohort. We reasoned 
that since CHOP represents a tertiary-care center in a developed 
country, one could reasonably expect differences in both base-
line mortality (intercept) as well as the effect of the variables 
on mortality (slope). Thus, both models were revised in the 
CHOP dataset using the same variables (Supplementary Table 
5, Supplemental Digital Content 1, http://links.lww.com/CCM/
F458). The revised models retained good discrimination (both 
AUROC ≥ 0.85), with the revised model for the entire intubated 
cohort continuing to demonstrate poor fit (Supplementary Fig. 
TABLE 2. Final Predictive Model for PICU Mortality in the Entire Pediatric Acute 
Respiratory Distress syndrome Incidence and Epidemiology Version 1 Cohort
Variable OR (95% CI)
Coefficient  
(95% CI)
Bayesian Information  
Criterion Increase
Immunocompromised 7.11 (3.96–12.75) 1.961 (1.38–2.55) 37
Pediatric Logistic Organ Dysfunction 2 day 0 1.21 (1.13–1.29) 0.189 (0.12–0.26) 34
Vasopressor-inotrope score day 0 (per 1-point increase) 1.01 (1.01–1.02) 0.014 (0.01–0.02) 13
Pao2/Fio2 at 6 hr 0.99 (0.99–0.99) –0.005 (–0.01 to 0) 12
Fluid balance (mL/kg) day 0 1.01 (1.00–1.01) 0.005 (0–0.01) 11
Constant — –2.910 (–3.65 to –2.17) —
OR = odds ratio.
Increase in Bayesian information criterion (BIC) lists the absolute amount the BIC increases if that particular variable is removed from the final model. Dashes 
indicate the variable has no interpretable OR.
TABLE 3. Predictive Utility, Internal Validation, and Fit of Models
Variable Whole Cohort
Whole Cohort  
Excluding Neurologic 
Deaths All Intubated
Intubated  
Excluding Neurologic  
Deaths
AUROCa 0.82 (0.78–0.87) 0.84 (0.79–0.89) 0.86 (0.81–0.90) 0.90 (0.86–0.94)
AUROCa (10-fold cross-validation) 0.81 (0.76–0.86) 0.83 (0.77–0.88) 0.85 (0.80–0.89) 0.84 (0.78–0.90)
Calibration belt p 0.785 0.857 0.838 0.249
AUROC = area under the receiver operating characteristic curve.
a All AUROC provided with 95% CIs.
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1C, Supplemental Digital Content 1, http://links.lww.com/CCM/
F458). The revised model excluding neurologic deaths demon-
strated improved fit (Supplementary Fig. 1D, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F458).
Utility of Mortality Prediction Models for 
Stratification of VFDs
As VFDs are commonly used as an outcome in PARDS, we 
assessed whether the four models developed for PICU mor-
tality appropriately stratified VFDs (Supplementary Fig. 
2, Supplemental Digital Content 1, http://links.lww.com/
CCM/F458). For models developed in the whole V1 cohort 
(Supplementary Fig. 2A, Supplemental Digital Content 1, 
http://links.lww.com/CCM/F458) and the V1 cohort ex-
cluding neurologic deaths (Supplementary Fig. 2B, Supple-
mental Digital Content 1, http://links.lww.com/CCM/F458), 
we assessed the relationship between quartiles of predicted 
mortality and probability of discontinuing total (invasive 
and noninvasive) ventilation, as not all subjects were intu-
bated. For the models restricted to intubated PARDS (Sup-
plementary Fig. 2C, Supplemental Digital Content 1, http://
links.lww.com/CCM/F458) and intubated PARDS excluding 
neurologic deaths (Supplementary Fig. 2D, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F458), we 
assessed the relationship between quartiles of predicted 
mortality and probability of extubation. For all four mod-
els, probability of successful discontinuation of ventilation 
was appropriately stratified by quartile, with lower proba-
bility of discontinuing ventilation (i.e., fewer VFDs) with 
higher predicted mortality. When we performed a parallel 
analysis in the CHOP validation cohort of intubated PARDS, 
both original (Supplementary Fig. 3, A and B, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F458) and re-
vised models (Supplementary Fig. 3, C and D, Supplemental 
Figure 1. Calibration belts for the separate models predicting PICU mortality in the Pediatric Acute Respiratory Distress syndrome Incidence and 
Epidemiology Version 1 (V1) cohort. The calibration belt examines the relationship between estimated probabilities and observed mortality rates, with 
associated 80% (light gray) and 95% (dark gray) CIs. Perfect calibration lies along the center (dashed) line. The calibration belt is paired to a statistic 
that tested deviation from the center line, similar to the Hosmer-Lemeshow test. All four models developed in the V1 cohort demonstrate good calibration 
(as indicated by p > 0.05 in all models).
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Digital Content 1, http://links.lww.com/CCM/F458) appro-
priately stratified VFDs.
Models for Ventilator Duration in Survivors
PARDIE V1 survivors (Supplementary Table 6, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F458) experi-
enced a median of 7.4 days (interquartile range, 4.1–13.0 d) of 
total (invasive and noninvasive) ventilation, and 6.1 days (in-
terquartile range, 3.1–11.3 d) of invasive ventilation. Factors 
associated with lower probability of discontinuing total venti-
lation included higher PELOD 2 and vasopressor score on day 
of PARDS diagnosis, presence of any comorbidity, and more 
PICU days before meeting PARDS criteria. Factors associated 
with lower probability of extubation included vasopressor score 
on day of PARDS diagnosis, OI at 6 hours after PARDS onset, 
PICU days before meeting PARDS criteria, and having greater 
than or equal to 15 PICU beds (Supplementary Table 7, Sup-
plemental Digital Content 1, http://links.lww.com/CCM/F458).
DISCUSSION
PARDS is a heterogeneous syndrome, and severity adjustment 
tools are important for clinical trial design. To date, there has 
not been a readily available and generalizable model for risk 
stratification in PARDS, with mortality prediction limited to 
models developed in few centers (13, 19, 20). We developed 
models for prediction of PICU mortality using variables from 
the first day of PARDS from a multinational cohort (Table 2; 
and Appendix 2, Supplemental Digital Content 1, http://links.
lww.com/CCM/F458). The models use readily available clinical 
data, demonstrate good discrimination and calibration, per-
form well in subgroups, and outperform published severity of 
illness scores. Several of the variables in the mortality models 
are implicated in duration of ventilation, and the mortality 
prediction model appropriately stratifies VFDs. We externally 
validated models developed for intubated subjects, thus directly 
addressing the generalizability concerns of previous models.
A variable selection strategy balancing parsimony and 
predictive utility protected against over-fitting and increased 
utility of the models by reducing the number of variables. 
All of the retained variables have been implicated in PARDS 
mortality, including immunocompromised status (13, 19) and 
organ failure (13, 20). Being from a middle-income country was 
retained as a predictor in the model excluding subjects dying 
from neurologic causes. This requires further investigation to 
TABLE 4. Performance (Area Under the Receiver Operating Characteristic Curve and 95% 
CI) of the Mortality Prediction Model Relative to Other Severity of Illness Scores and a 
Published Model for Predicting Pediatric Acute Respiratory Distress Syndrome Mortality
Cohorts
Derivation (Pediatric Acute Respiratory 
Distress syndrome Incidence and  
Epidemiology Version 1)
Validation  
(Children’s Hospital  
of Philadelphia)
Intubated cohorta
 Modelb
  Original 0.86 (0.81–0.90) 0.85 (0.81–0.89)
  Revised — 0.85 (0.81 to 0.89)
 PIM 3 0.71 (0.65–0.77) 0.70 (0.63–0.78)
 PRISM IV 0.77 (0.72–0.82) 0.75 (0.69–0.80)
 PELOD 2 0.72 (0.67–0.78) 0.74 (0.68–0.80)
 OI at 6 hr + oncology/stem cell transplant 0.76 (0.70–0.82) 0.70 (0.64–0.76)
Intubated excluding neurologic deathsa
 Modelb
  Original 0.90 (0.86–0.94) 0.91 (0.87–0.94)
  Revised — 0.91 (0.87–0.95)
 PIM 3 0.68 (0.60–0.75) 0.58 (0.49–0.68)
 PRISM IV 0.75 (0.69–0.81) 0.65 (0.57–0.72)
 PELOD 2 0.72 (0.65–0.79) 0.71 (0.63–0.79)
 OI at 6 hr + oncology/stem cell transplant 0.80 (0.74–0.86) 0.84 (0.79–0.90)
OI = oxygenation index, PELOD = Pediatric Logistic Organ Dysfunction, PIM = Pediatric Index of Mortality, PRISM = Pediatric Risk of Mortality.
a We only presented comparisons of the models developed for intubated subjects, as the published simplified pediatric acute respiratory distress syndrome 
(PARDS) prediction model was restricted to intubated PARDS.
b When comparing area under the receiver operating characteristic curve using Stata "roccomp" (StataCorp, College Station, TX), the predictive model 
outperformed the severity of illness scores and the simplified prediction model (p < 0.05 for all comparisons).
Dashes indicate the the revision only occurred in the Validation cohort.
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identify potential causes of an apparent association between 
geoeconomic status and mortality. Notably, this is consistent 
with the lower survival in adults with ARDS from middle-
income countries seen in the Large Observational Study to 
Understand the Global Impact of Severe Acute Respiratory 
Failure (14). However, it is important to note that only 13% of 
subjects in PARDIE V1 were from a middle-income country, 
with complete absence of African representation, limiting any 
definitive inferences regarding this association.
As in previous studies (16), hypoxemia was responsible for 
a minority of deaths, whereas MSOF and neurologic etiologies 
were responsible for a larger fraction. In both adult ARDS (21, 
22) and PARDS (8, 16, 20), neurologic etiologies of death are 
common. Many of these subjects would be excluded from clin-
ical trials due to their neurologic prognosis (22), yet are com-
monly retained in observational studies, contributing to lower 
than expected mortality rates in trials. The separate model 
for intubated patients excluding subjects dying of neurologic 
causes thus may have greatest utility in clinical trials, as this 
most closely resembles trial populations, with the caveat that 
neurologic status may be difficult to assess at PARDS onset.
VFDs are commonly used in trials of adult ARDS and in 
PARDS. As mortality in pediatrics is lower than adults (12, 23), 
ventilator duration in survivors is an important contributor to 
calculating VFDs. For both models predicting ventilator dura-
tion (total and invasive ventilation), variables with the highest 
importance were also present in the models predicting mor-
tality. Overall, this supports the utility of the mortality predic-
tion models for predicting other clinically relevant outcomes, 
such as VFDs, which we demonstrated in both the derivation 
(Supplementary Fig. 2, Supplemental Digital Content 1, http://
links.lww.com/CCM/F458) and validation (Supplementary 
Fig. 3, Supplemental Digital Content 1, http://links.lww.com/
CCM/F458) cohorts.
Models for intubated subjects were validated in a prospec-
tive cohort from CHOP, a large, tertiary-care North American 
PICU restricted to invasively ventilated subjects with Berlin 
ARDS, requiring arterial access and bilateral infiltrates. This 
cohort had higher vasopressor scores, better oxygenation, and 
more neurologic deaths than the V1 cohort. When comparing 
the coefficients between the original derivation (Supplementary 
Table 3, Supplemental Digital Content 1, http://links.lww.
com/CCM/F458) and the revised (Supplementary Table 5, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
F458) models, several coefficients demonstrated downward 
attenuation. For example, in the revised model for the entire 
intubated CHOP cohort, the coefficient for PELOD 2 was 27% 
lower, the coefficient for immunocompromised status was 
38% lower, and the coefficient for OI was 34% lower. These 
results suggest that the impact of these variables on mortality 
is lower in the CHOP cohort, and that fit remains poor because 
even this revised model does not capture the best predictors 
of mortality in this specific PICU, despite identical discrimi-
nation (Table 4). Notwithstanding this limitation, the model 
and variables elected may retain some utility, as both original 
and revised models appropriately stratify VFDs in the CHOP 
cohort (Supplementary Fig. 3, Supplemental Digital Content 1, 
http://links.lww.com/CCM/F458).
The greater percentage of neurologic deaths at CHOP may 
also contribute to the poor fit, despite revision, of the model 
developed for all intubated subjects. Notably, the model ex-
cluding neurologic deaths demonstrated perfect fit after re-
vision, confirming that cause of death may be impacting the 
utility of the models. This suggests that, in addition to recali-
bration or revision, models both including and excluding neu-
rologic deaths need to be tested in a given setting.
We believe that the models offered here are a first step to-
ward improved outcome prediction in PARDS, confirming that 
a few readily available clinical variables can stratify mortality 
risk, which will assist with prognostic enrichment for trials (6), 
and for identifying heterogeneity of treatment effect post hoc 
(7). We expect further refinement and encourage additional 
external validation of these models in other PARDS cohorts, 
particularly in traditionally underrepresented settings.
Strengths of our study include model development in a 
large, modern, multinational cohort; good internal validation 
and calibration; and external validation in a separate, large 
cohort. Our conclusions are based on observations in greater 
than 1,200 children with PARDS. However, there are limita-
tions to our study. First, variables such as PELOD 2 score, fluid 
balance, and vasopressor score were collected for the calendar 
day of PARDS diagnosis, with no adjustment for whether that 
encompassed 24 hours or a shorter interval. Second, our pri-
mary outcome was PICU mortality, rather than hospital mor-
tality, as we reasoned that factors associated with acute PARDS 
are more likely to affect short-term outcomes, while under-
lying comorbidities may be more responsible for longer-term 
outcomes. Third, external validation was only performed in a 
single-center cohort with different eligibility criteria. Other ex-
ternal validation cohorts which were considered were missing 
necessary data elements, precluding testing of these models. 
Accordingly, we believe future PARDS studies should routinely 
collect these data elements. Fourth, as our focus was on accu-
rate risk stratification for clinical trials, we only tested variables 
on day 0 of PARDS, which is within the timeframe for recruit-
ment for most studies. The utility of longitudinal models is un-
known, but it is possible that these would be an improvement 
over a static day 0 model. Finally, while an improvement upon 
existing models, performance of the models for mortality pre-
diction are inadequate to support clinical utility for bedside 
prognostication at this time.
CONCLUSIONS
We developed and validated predictive models for PICU mor-
tality in PARDS with good performance, which can assist with 
risk stratification for clinical trials. Development of models ex-
cluding neurologic deaths may be of particular utility, as they 
commonly exclude such subjects. Several variables associated 
with mortality are also implicated in duration of ventilation, 
and we confirmed utility of models for stratifying VFDs. All 
variables represent routinely available clinical data from the 
first day of PARDS, and should consistently be collected in 
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future investigations. At this time, model performance is in-
adequate to support clinical utility at bedside. Studies are war-
ranted to further validate and update these models in other 
PARDS cohorts, and to test whether operationalized use of the 
model is feasible in a trial.
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